Multi-Agonism
Explore peptide research and guides on multi-agonism.
Multi-Agonism
Dual vs Triple Agonist Peptides: Is More Better?
Tirzepatide (dual) and retatrutide (triple) target different receptor combinations. We compare the clinical data on weight loss, side effects, and tradeoffs.
Multi-AgonismMore Receptors, More Weight Loss? The Multi-Agonist Science
Multi-agonist peptides target GLP-1, GIP, and glucagon receptors at once. Retatrutide hit 24.2% weight loss in phase 2, the most ever for any drug.
Multi-AgonismMulti-Agonism's Ceiling: Do More Receptors Mean More?
Dual and triple GLP-1/GIP/glucagon agonists produce escalating weight loss, but each added receptor brings diminishing gains and rising side effects.